Benzinga | Sep 30, 2021 07:15AM EDT

Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail

* Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holdings AG (OTC:RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitalized COVID-19 patients.

* Related: WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access.

* The trial met its primary endpoint and showed that REGEN-COV significantly reduced viral load in hospitalized patients within seven days of treatment without mounting their antibody response (seronegative) and required low-flow or no supplemental oxygen.

* The full results of the study will be presented at ID Week 2021 today.

* In this trial, patients who received REGEN-COV experienced a 36% reduced risk of dying within 29 days of treatment. In patients who were seronegative when they entered the trial, the risk was reduced by 56%.

* In a safety analysis involving 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients.

* Infusion-related and hypersensitivity reactions were more common among REGEN-COV patients (2% and 1% respectively) than placebo patients (1% and less than 0.5%, respectively).

* The study also reported results supportive of the much larger UK RECOVERY trial in hospitalized patients.

* It showed that patients who received Ronapreve (2,400 mg or 8,000 mg) along with standard care experienced numeric improvements across all clinical endpoints assessed, compared to standard care alone.

* Comparable clinical outcomes were recorded with both 2,400 mg and 8,000 mg doses. No new safety signals were identified.

* Read Next: FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis.

* Price Action: REGN stock closed at $606.70 on Wednesday.